The expression level of PD-1 in TNM I/II patients was significantly higher than that in III/IV patients (16.0±5.9 vs. 9.7±8.1 pg/ml, p=0.012), suggesting that sPD-1 may be a biomarker for the development of NPC. Here, PDCD1 is linked to nasopharyngeal carcinoma.